About Apollo Endosurgery (NASDAQ:APEN)
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company sells its products primarily in the United States, Europe, Australia, Brazil, and Canada. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APEN
CUSIPN/A
Phone512-279-5100
Debt
Debt-to-Equity Ratio0.67%
Current Ratio2.23%
Quick Ratio1.68%
Price-To-Earnings
Trailing P/E Ratio-2.91
Forward P/E Ratio-4.15
P/E GrowthN/A
Sales & Book Value
Annual Sales$64.31 million
Price / Sales1.58
Cash FlowN/A
Price / CashN/A
Book Value$2.89 per share
Price / Book2.02
Profitability
EPS (Most Recent Fiscal Year)($2.01)
Net Income$-27,290,000.00
Net Margins-42.35%
Return on Equity-64.48%
Return on Assets-27.44%
Miscellaneous
Employees213
Outstanding Shares17,340,000
Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions
What is Apollo Endosurgery's stock symbol?
Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."
How were Apollo Endosurgery's earnings last quarter?
Apollo Endosurgery (NASDAQ:APEN) announced its quarterly earnings results on Thursday, March, 1st. The biotechnology company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.34) by $0.08. The biotechnology company earned $16.14 million during the quarter, compared to analysts' expectations of $16.64 million. Apollo Endosurgery had a negative net margin of 42.35% and a negative return on equity of 64.48%. View Apollo Endosurgery's Earnings History.
What price target have analysts set for APEN?
4 equities research analysts have issued 12 month price targets for Apollo Endosurgery's stock. Their predictions range from $8.00 to $12.00. On average, they anticipate Apollo Endosurgery's share price to reach $10.25 in the next twelve months. View Analyst Ratings for Apollo Endosurgery.
What are Wall Street analysts saying about Apollo Endosurgery stock?
Here are some recent quotes from research analysts about Apollo Endosurgery stock:
- 1. According to Zacks Investment Research, "Apollo Endosurgery, Inc. is engaged in designing and manufacturing of medical devices for weight loss solutions and gastrointestinal disorders. The Company's product segment includes ORBERA (R), LAP-BAND (R) and OverStitch(TM). The ORBERA is an Intragastric Balloon System which is a weight loss aid for adults suffering from obesity. The LAP-BAND System is developed for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables endoscopic surgery. It operates primarily in Asia Pacific, European Office, Latin and South America and Costa Rica. Apollo Endosurgery, Inc., formerly known as Lpath, Inc., is headquatered in Austin, Texas. " (3/6/2018)
- 2. Northland Securities analysts commented, "We note that the ASMBS Statement is not a guarantee of reimbursement for Orbera." (2/8/2018)
Who are some of Apollo Endosurgery's key competitors?
Some companies that are related to Apollo Endosurgery include Nuvectra (NVTR), SeaSpine (SPNE), IRadimed (IRMD), Restoration Robotics (HAIR), Alphatec (ATEC), Invuity (IVTY), Obalon Therapeutics (OBLN), Neovasc (NVCN), Arch Therapeutics (ARTH), Presbia (LENS), Cellect Biotechnology (APOP), Interpace Diagnostics Gr (IDXG), AIT Therapeutics (AITB), Cytori Therapeutics (CYTX), Valeritas (VLRX), InVivo Therapeutics (NVIV), Alliqua BioMedical (ALQA) and Neurometrix (NURO).
Who are Apollo Endosurgery's key executives?
Apollo Endosurgery's management team includes the folowing people:
- Mr. Todd Newton, CEO & Director (Age 55)
- Mr. Charles Tribié, Exec. VP of Operations (Age 65)
- Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
- Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
- Dr. Robert Hawes M.D., Co-Founder and Innovation Partner
Has Apollo Endosurgery been receiving favorable news coverage?
Media stories about APEN stock have trended somewhat positive this week, according to Accern Sentiment. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Apollo Endosurgery earned a news impact score of 0.16 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 47.44 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
How do I buy shares of Apollo Endosurgery?
Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apollo Endosurgery's stock price today?
One share of APEN stock can currently be purchased for approximately $5.85.
How big of a company is Apollo Endosurgery?
Apollo Endosurgery has a market capitalization of $102.28 million and generates $64.31 million in revenue each year. The biotechnology company earns $-27,290,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. Apollo Endosurgery employs 213 workers across the globe.
How can I contact Apollo Endosurgery?
Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]
MarketBeat Community Rating for Apollo Endosurgery (APEN)
MarketBeat's community ratings are surveys of what our community members think about Apollo Endosurgery and other stocks. Vote "Outperform" if you believe APEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Apollo Endosurgery (NASDAQ:APEN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Apollo Endosurgery in the last 12 months. Their average twelve-month price target is $10.25, suggesting that the stock has a possible upside of 75.21%. The high price target for APEN is $12.00 and the low price target for APEN is $8.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $10.25 | $11.00 | $11.00 | $11.00 |
| Price Target Upside: | 75.21% upside | 79.74% upside | 89.00% upside | 139.65% upside |
Apollo Endosurgery (NASDAQ:APEN) Consensus Price Target History
Apollo Endosurgery (NASDAQ:APEN) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Apollo Endosurgery (NASDAQ:APEN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Apollo Endosurgery (NASDAQ APEN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 52.80%
Institutional Ownership Percentage: 31.20%
Apollo Endosurgery (NASDAQ APEN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/9/2018 | Matthew S Crawford | Director | Buy | 4,038 | $6.20 | $25,035.60 | 53,715 |  |
| 1/3/2018 | Stonepine Capital, L.P. | Major Shareholder | Buy | 22,845 | $5.71 | $130,444.95 | 2,560,314 | |
| 12/29/2017 | Stonepine Capital, L.P. | Major Shareholder | Buy | 5,163 | $5.56 | $28,706.28 | 2,560,314 | |
| 12/26/2017 | Stonepine Capital, L.P. | Major Shareholder | Buy | 5,287 | $5.00 | $26,435.00 | 2,555,151 | |
| 12/22/2017 | Stonepine Capital, L.P. | Major Shareholder | Buy | 185,157 | $4.85 | $898,011.45 | 2,410,141 | |
| 12/20/2017 | Stonepine Capital, L.P. | Major Shareholder | Buy | 45,434 | $4.50 | $204,453.00 | 2,410,141 | |
| 11/7/2017 | Bret Schwartzhoff | VP | Buy | 9,500 | $4.24 | $40,280.00 | 15,631 | |
| 7/26/2017 | Holdings A/S Novo | Major Shareholder | Sell | 50,130 | $6.90 | $345,897.00 | 1,334,772 | |
| 7/25/2017 | Richard J Meelia | Director | Buy | 45,454 | $5.50 | $249,997.00 | 5,098 | |
| 7/25/2017 | Sciences L P Ptv II | Major Shareholder | Buy | 1,090,909 | $5.50 | $5,999,999.50 | | |
| 7/25/2017 | Stefanie L Cavanaugh | CFO | Buy | 4,545 | $5.50 | $24,997.50 | 9,166 | |
| 7/25/2017 | Todd Newton | CEO | Buy | 136,363 | $5.50 | $749,996.50 | 167,129 | |
| 5/18/2017 | Todd Newton | CEO | Buy | 2,121 | $6.22 | $13,192.62 | 29,544 | |
| 5/17/2017 | William D Jr. Mcclellan | Director | Buy | 2,000 | $6.33 | $12,660.00 | | |
| 5/11/2017 | A/S Novo | Major Shareholder | Sell | 105,000 | $5.63 | $591,150.00 | 1,455,472 | |
| 12/12/2014 | Daniel H Petree | Director | Buy | 10,000 | $2.79 | $27,900.00 | | |
| 8/20/2014 | Gary J G Atkinson | CFO | Buy | 5,000 | $3.10 | $15,500.00 | | |
| 8/19/2014 | Scott R Pancoast | CEO | Buy | 10,000 | $3.00 | $30,000.00 | | |
| 8/18/2014 | Scott R Pancoast | CEO | Buy | 10,000 | $3.22 | $32,200.00 | | |
| 12/19/2012 | Charles Mathews | Director | Buy | 5,000 | $4.98 | $24,900.00 | | |
| 12/18/2012 | Scott R Pancoast | CEO | Buy | 5,000 | $4.95 | $24,750.00 | | |
(Data available from 1/1/2013 forward)
Apollo Endosurgery (NASDAQ APEN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Apollo Endosurgery (APEN) Receives New Coverage from Analysts at Roth Capital
www.americanbankingnews.com - April 14 at 10:19 AM |
| Comparing Apollo Endosurgery (APEN) and The Competition
www.americanbankingnews.com - April 14 at 3:17 AM |
| Financial Contrast: Apollo Endosurgery (APEN) vs. Its Rivals
www.americanbankingnews.com - April 13 at 9:19 PM |
| Apollo Endosurgery (APEN) Downgraded by ValuEngine to "Strong Sell"
www.americanbankingnews.com - April 13 at 2:49 PM |
| Apollo Endosurgery (APEN) Earns Overweight Rating from Analysts at Piper Jaffray
www.americanbankingnews.com - April 13 at 10:37 AM |
| Apollo Endosurgery (APEN) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 13 at 9:31 AM |
| Apollo Endosurgery (APEN) Expected to Announce Quarterly Sales of $16.00 Million
www.americanbankingnews.com - April 10 at 2:21 AM |
| -$0.38 EPS Expected for Apollo Endosurgery (APEN) This Quarter
www.americanbankingnews.com - April 8 at 7:10 PM |
| Zacks: Apollo Endosurgery Inc (APEN) Given $10.83 Consensus Price Target by Analysts
www.americanbankingnews.com - March 31 at 3:18 PM |
| Apollo Endosurgery (APEN) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 31 at 1:04 PM |
| Apollo Endosurgery Inc (APEN) Expected to Post Quarterly Sales of $16.00 Million
www.americanbankingnews.com - March 24 at 7:44 AM |
| Brokerages Anticipate Apollo Endosurgery Inc (APEN) Will Post Earnings of -$0.39 Per Share
www.americanbankingnews.com - March 22 at 7:10 PM |
| Apollo Endosurgery (APEN) and Utah Medical Products (UTMD) Critical Contrast
www.americanbankingnews.com - March 22 at 3:10 AM |
 | Apollo Endosurgery Announces Conclusion of LAP-BAND® Low BMI Post-Approval Study
finance.yahoo.com - March 20 at 9:52 AM |
| Apollo Endosurgery Inc (APEN) Director Matthew S. Crawford Acquires 4,038 Shares
www.americanbankingnews.com - March 13 at 8:52 PM |
| Apollo Endosurgery (APEN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - March 6 at 4:42 PM |
| Stonepine Capital Management LLC Has $14.34 Million Holdings in Apollo Endosurgery Inc (APEN)
www.americanbankingnews.com - March 6 at 2:53 PM |
| Analysts Expect Apollo Endosurgery Inc (APEN) Will Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - March 5 at 3:10 PM |
| Analysts Set $10.83 Target Price for Apollo Endosurgery Inc (APEN)
www.americanbankingnews.com - March 2 at 11:22 PM |
| Apollo Endosurgery, Inc. Reports Fourth Quarter and Full Year 2017 Results
finance.yahoo.com - March 1 at 4:40 PM |
 | Apollo Endosurgery (APEN) Endosurgery Announces First ORBERA U.S. Post-Approval Publication
www.streetinsider.com - February 27 at 4:53 PM |
| Apollo Endosurgery Announces First ORBERA® U.S. Post-Approval Publication
finance.yahoo.com - February 27 at 9:41 AM |
 | BRIEF-Apollo Endosurgery Announces MFDS Approval For Orbera Intragastric Balloon System
www.reuters.com - February 23 at 9:35 AM |
| Apollo Endosurgery Announces MFDS Approval for the ORBERA® Intragastric Balloon System in South Korea, a Non-Surgical Solution to Assist Patients with Weight Loss
finance.yahoo.com - February 22 at 4:42 PM |
| Apollo Endosurgery, Inc. to Report Fourth Quarter and Full Year 2017 Results on March 1, 2018
finance.yahoo.com - February 22 at 9:27 AM |
| Zacks: Brokerages Anticipate Apollo Endosurgery Inc (APEN) Will Announce Quarterly Sales of $16.64 Million
www.americanbankingnews.com - February 18 at 1:46 AM |
| -$0.34 EPS Expected for Apollo Endosurgery Inc (APEN) This Quarter
www.americanbankingnews.com - February 16 at 11:08 PM |
| Northland Securities Reaffirms "Buy" Rating for Apollo Endosurgery (APEN)
www.americanbankingnews.com - February 8 at 11:18 AM |
| Zacks: Analysts Anticipate Apollo Endosurgery Inc (APEN) Will Post Earnings of -$0.34 Per Share
www.americanbankingnews.com - January 30 at 11:10 PM |
| Brokerages Anticipate Apollo Endosurgery Inc (APEN) Will Post Earnings of -$0.34 Per Share
www.americanbankingnews.com - January 14 at 1:06 AM |
| Apollo Endosurgery (APEN) PT Set at $10.00 by Roth Capital
www.americanbankingnews.com - January 8 at 12:44 AM |
| Apollo Endosurgery Inc (APEN) Major Shareholder Stonepine Capital, L.P. Acquires 5,163 Shares
www.americanbankingnews.com - January 3 at 7:54 PM |
| Stonepine Capital, L.P. Purchases 22,845 Shares of Apollo Endosurgery Inc (APEN) Stock
www.americanbankingnews.com - January 3 at 7:28 PM |
| Apollo Endosurgery, Inc. (APEN) Expected to Announce Quarterly Sales of $16.67 Million
www.americanbankingnews.com - December 30 at 1:50 PM |
| $16.67 Million in Sales Expected for Apollo Endosurgery, Inc. (APEN) This Quarter
www.americanbankingnews.com - December 30 at 12:14 PM |
| Analysts Anticipate Apollo Endosurgery, Inc. (APEN) Will Post Quarterly Sales of $16.67 Million
www.americanbankingnews.com - December 30 at 12:14 PM |
| Stonepine Capital, L.P. Buys 5,287 Shares of Apollo Endosurgery, Inc. (APEN) Stock
www.americanbankingnews.com - December 28 at 7:30 PM |
| -$0.33 Earnings Per Share Expected for Apollo Endosurgery, Inc. (APEN) This Quarter
www.americanbankingnews.com - December 28 at 8:30 AM |
| Zacks Investment Research Lowers Apollo Endosurgery (APEN) to Hold
www.americanbankingnews.com - December 27 at 5:00 PM |
| Insider Buying: Apollo Endosurgery, Inc. (APEN) Major Shareholder Buys 185,157 Shares of Stock
www.americanbankingnews.com - December 22 at 8:39 PM |
| Stonepine Capital, L.P. Buys 45,434 Shares of Apollo Endosurgery, Inc. (APEN) Stock
www.americanbankingnews.com - December 22 at 8:39 PM |
| Apollo Endosurgery (APEN) Files to Offer $16M in Common Stock
www.streetinsider.com - December 21 at 10:39 AM |
| Zacks: Brokerages Anticipate Apollo Endosurgery, Inc. (APEN) Will Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - December 10 at 11:32 PM |
| Apollo Endosurgery (APEN) Rating Reiterated by Northland Securities
www.americanbankingnews.com - December 4 at 11:38 AM |
 | Apollo Endosurgery Inc. (APEN) Leaped After FDA Clearance
www.rttnews.com - November 30 at 4:15 PM |
| Apollo Endosurgery (APEN) Announces FDA Clearance for OverStitch Sx Endoscopic Suturing System
www.streetinsider.com - November 28 at 11:43 AM |
 | Apollo Endosurgery's stock rockets on FDA clearance of OverStitch Sx
www.marketwatch.com - November 28 at 11:43 AM |
| Apollo Endosurgery Inc. (APEN) Is Surging After Receiving FDA Clearance
www.rttnews.com - November 28 at 11:43 AM |
 | Apollo Endosurgery Surges on FDA Approval
247wallst.com - November 28 at 11:43 AM |
| Apollo Endosurgery Inc (APEN) Sparks Optimism Among Investors; Here’s Why
finance.yahoo.com - November 28 at 11:43 AM |
Apollo Endosurgery (NASDAQ:APEN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Apollo Endosurgery (NASDAQ:APEN) Income Statement, Balance Sheet and Cash Flow Statement
Apollo Endosurgery (NASDAQ APEN) Stock Chart for Saturday, April, 21, 2018
Loading chart…
